Literature DB >> 11882749

How many patients complete an adequate trial of donepezil?

Catherine M Roe1, Michael J Anderson, Barney Spivack.   

Abstract

Pharmacy claims data were used to evaluate medication adherence among 59 new users of donepezil aged 65 to 94 years. The probability (+/- 95% confidence interval) of a new user continuing donepezil at 90 days was.797 +/-.103 and at 180 days was.627 +/-.124. Additionally, 13.9% of those who continued therapy for at least 180 days showed gaps in treatment of six weeks or more. These results suggest that adherence with donepezil could be improved in clinical practice.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11882749     DOI： 10.1097/00002093-200201000-00008

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN： 0893-0341            Impact factor:   2.703


  9 in total

Review 1.  Medication (re)fill adherence measures derived from pharmacy claims data in older Americans: a review of the literature.

Authors:  Elisabeth Lilian Pia Sattler; Jung Sun Lee; Matthew Perri
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

Review 2.  Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors.

Authors:  Colleen J Maxwell; Kathryn Stock; Dallas Seitz; Nathan Herrmann
Journal:  Can J Psychiatry       Date:  2014-12       Impact factor: 4.356

3.  Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease.

Authors:  Dong-Churl Suh; Simu K Thomas; Elmira Valiyeva; Stephen Arcona; Lien Vo
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 4.  Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease.

Authors:  Ben Seltzer
Journal:  Clin Interv Aging       Date:  2010-02-02       Impact factor: 4.458

5.  Noncompliance with Treatment of Neurologic Disease.

Authors:  Jeffrey S. Nicholl
Journal:  Curr Treat Options Neurol       Date:  2002-11       Impact factor: 3.598

6.  Compliance assessment of ambulatory Alzheimer patients to aid therapeutic decisions by healthcare professionals.

Authors:  Oliver Schwalbe; Christian Scheerans; Ines Freiberg; Andrea Schmidt-Pokrzywniak; Andreas Stang; Charlotte Kloft
Journal:  BMC Health Serv Res       Date:  2010-08-09       Impact factor: 2.655

Review 7.  Treatment of vascular risk factors in patients with a diagnosis of Alzheimer's disease: a systematic review.

Authors:  Raffaella Valenti; Leonardo Pantoni; Hugh S Markus
Journal:  BMC Med       Date:  2014-11-11       Impact factor: 8.775

8.  Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program.

Authors:  Susan M Abughosh; Stephen J Kogut
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

9.  Donepezil Adherence, Persistence and Time to First Discontinuation in a Three-Year Follow-Up of Older People.

Authors:  Henry C Ndukwe; Prasad S Nishtala
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2015-12-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.